Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × NIH × Ketamine × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1 Terminated 1

Sponsor Class

OTHER 9 NIH 1 FED 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Fatigue 1

Interventions

Cyclophosphamide 42 aldesleukin 26 fludarabine phosphate 23 fludarabine 23 Carboplatin 17 Rituximab 15 Bevacizumab 15 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 15 Radiotherapy 13 Interleukin-2 13 Cisplatin 13 Bortezomib 13 Paclitaxel 12 Erlotinib Hydrochloride 12 Leucovorin 11 Filgrastim 11 Etoposide 11 Doxorubicin 11 Oxaliplatin 10 Magnetic Resonance Spectroscopy 10 Fluorouracil 10 Sorafenib 9 Radiation 9 Dexamethasone 9 Biopsy 9 Vincristine 8 Taxes 8 Docetaxel 8 Decitabine 8 Capecitabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02317341 2019-03-20

Effect of Ketamine on Fatigue Following Cancer Therapy

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡